Day: January 21, 2025

First patient enrolled in the VAR2 Pharma – TRACER Phase 0 oncology trial

GRONINGEN, NETHERLANDS (21 January 2025) – TRACER and VAR2 Pharma announce the first patient enrolled in the VARTUTRACE study, a Phase 0 first-in-human imaging trial (NCT06645808). The patient, suffering from lung carcinoma received the Investigational Medicinal Product (IMP), a zirconium-89-labeled single-chain variable fragment (scFv), Vartumab, on Dec 17, 2024. The patient successfully completed all study […]